Knight Therapeutics Inc.
KHTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | 0.02 | -0.86 | 0.00 |
| FCF Yield | 1.65% | -0.85% | -0.01% | 0.08% |
| EV / EBITDA | 35.01 | -545.34 | 42.24 | 19.49 |
| Quality | ||||
| ROIC | 0.14% | -0.33% | 3.47% | -0.46% |
| Gross Margin | 33.21% | 41.76% | 39.59% | 41.66% |
| Cash Conversion Ratio | -2.78 | -1.60 | 1.68 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.18% | 5.61% | 6.07% | 8.15% |
| Free Cash Flow Growth | 249.37% | -15,629.03% | -107.87% | -86.74% |
| Safety | ||||
| Net Debt / EBITDA | 1.34 | -24.52 | -4.50 | -1.26 |
| Interest Coverage | 0.27 | -1.55 | -3.15 | -1.21 |
| Efficiency | ||||
| Inventory Turnover | 0.56 | 0.42 | 0.38 | 0.55 |
| Cash Conversion Cycle | 131.33 | 153.21 | 166.18 | 144.27 |